Alfouzan Wadha, Altawalah Haya, AlSarraf Ahmad, Alali Walid, Al-Fadalah Talal, Al-Ghimlas Fahad, Alajmi Saud, Alajmi Mubarak, AlRoomi Ebtehal, Jeragh Ahlam, Dhar Rita
Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait City 46300, Kuwait.
Microbiology Unit, Department of Laboratory Medicine, Farwania Hospital, Ministry of Health, Kuwait City 85000, Kuwait.
Vaccines (Basel). 2023 Feb 2;11(2):336. doi: 10.3390/vaccines11020336.
We sought to assess pre-vaccination and post-vaccination seroprevalences of anti-SARS-CoV-2 antibodies in Kuwait and to compare antibody levels between vaccine types. In phase 1 (pre-vaccination period, = 19,363), blood samples were collected before the launch of COVID-19 vaccination in Kuwait between 1 September and 31 December 2020. Blood samples for phase 2 (post-vaccination period, = 4973) were collected between 1 September and 30 November 2021. We tested subjects for anti-SARS-CoV-2 antibodies using the DiaSorin LIAISON SARS-CoV-2 IgM and Trimeric S IgG tests. In the pre-vaccination period, the prevalence of SARS-CoV-2 IgM and IgG was 14.50% (95% CI: 14.01-15.00) and 24.89% (95% CI: 24.29-25.50), respectively. The trend of seropositivity increased with age and was higher for females and non-Kuwaiti participants ( < 0.0001). Interestingly, seroprevalence was significantly higher for those who had received one dose of BNT162b2 (95.21%) than those who had received one dose of ChAdOx1-nCov-19 (92.86%). In addition, those who reported receiving two doses had higher seroprevalence, 96.25%, 95.86%, and 94.93% for ChA-dOx1-nCov-19/AstraZeneca, mix-and-match, and BNT162b2 recipients, respectively. After the second dose, median spike-specific responses showed no significant difference between ChAdOx1-nCov-19 and BNT162b2. Furthermore, statistical analysis showed no significant difference between median anti-trimeric S antibody levels of vaccinated individuals according to sex, age, or nationality ( > 0.05). In contrast, a negative correlation between age and anti-trimeric S IgG titers of BNT162b2-vaccinated subjects was observed (r = -0.062, = 0.0009). Antibody levels decreased with time after vaccination with both vaccines. Our findings indicate that seroprevalence was very low during the pre-vaccination period (25%) in the general population and was greater than 95% in the vaccinated population in Kuwait. Furthermore, ChAdOx1-nCov-19 and BNT162b2 are effective in generating a similar humoral response.
我们旨在评估科威特人群接种新冠疫苗前后抗SARS-CoV-2抗体的血清阳性率，并比较不同疫苗类型之间的抗体水平。在第一阶段（接种疫苗前时期，n = 19363），于2020年9月1日至12月31日在科威特新冠疫苗接种启动前采集血样。第二阶段（接种疫苗后时期，n = 4973）的血样于2021年9月1日至11月30日采集。我们使用DiaSorin LIAISON SARS-CoV-2 IgM和三聚体S IgG检测对受试者进行抗SARS-CoV-2抗体检测。在接种疫苗前时期，SARS-CoV-2 IgM和IgG的阳性率分别为14.50%（95%CI：14.01 - 15.00）和24.89%（95%CI：24.29 - 25.50）。血清阳性率的趋势随年龄增加，女性和非科威特参与者的阳性率更高（P < 0.0001）。有趣的是，接种一剂BNT162b2的人群血清阳性率（95.21%）显著高于接种一剂ChAdOx1-nCov-19的人群（92.86%）。此外，报告接种两剂疫苗的人群血清阳性率更高，接种ChAdOx1-nCov-19/阿斯利康、混合接种以及BNT162b2的人群血清阳性率分别为96.25%、95.86%和94.93%。在接种第二剂后，ChAdOx1-nCov-19和BNT162b2之间的刺突蛋白特异性反应中位数无显著差异。此外，统计分析显示，根据性别、年龄或国籍，接种疫苗个体的抗三聚体S抗体水平中位数之间无显著差异（P > 0.05）。相比之下，观察到接种BNT162b2的受试者年龄与抗三聚体S IgG滴度之间呈负相关（r = -0.062，P = 0.0009）。两种疫苗接种后抗体水平均随时间下降。我们的研究结果表明，科威特普通人群在接种疫苗前时期血清阳性率非常低（25%），而接种疫苗人群的血清阳性率大于95%。此外，ChAdOx1-nCov-19和BNT162b2在产生相似的体液免疫反应方面是有效的。
Zotero 插件
